Table 1.
Characteristics of patients with a uveal melanoma (UM) that underwent enucleation in the Leiden University Medical Center (LUMC) between 1999 and 2016 (n = 108), categorised as soluble HLA (sHLA) negative or sHLA positive, based on the level of sHLA in the aqueous humour.
| Clinical and Histopathologic Characteristics | Patients, n (%) a | ||
|---|---|---|---|
| sHLA Negative (n = 89) | sHLA Positive (n = 19) | p-Value * | |
| Gender | 0.09 b | ||
| Female | 33 (37) | 11 (58) | |
| Male | 56 (63) | 8 (42) | |
| Previous tumour treatment prior to enucleation | 0.69 d | ||
| No | 86 (97) | 18 (95) | |
| Yes | 3 (3) | 1 (5) | |
| Eye | 0.28 b | ||
| OD | 52 (58) | 7 (37) | |
| OS | 37 (42) | 12 (63) | |
| Age at enucleation | 0.46 e | ||
| in years, mean (±S.D.) | 59 (±14) | 63 (±16) | |
| Eye colour c (known in 58 cases) | 0.056 b | ||
| Light | 49 (88) | 10 (67) | |
| Dark | 7 (12) | 5 (33) | |
| Largest basal tumour diameter | 0.40 e | ||
| in mm, mean (±S.D.) (known in 107 cases) | 12.3 (±3.1) | 13.1 (±3.1) | |
| Tumour prominence | <0.001 e,* | ||
| in mm, mean (±S.D.) (known in 107 cases) | 7.0 (±2.9) | 9.8 (±2.2) | |
| Ciliary body involvement | <0.001 b,* | ||
| No | 64 (72) | 5 (26) | |
| Yes | 25 (28) | 14 (74) | |
| Mitotic count f (known in 101 cases) | 0.44 e | ||
| mean (±S.D.) | 4.7 (±3.3) | 6.4 (±7.1) | |
| Histopathologic cell type | 0.064 b | ||
| Spindle cell | 28 (32) | 2 (11) | |
| Epithelioid or mixed cell type | 61 (69) | 17 (89) | |
| Bruch’s membrane (known in 104 cases) | 0.076 d | ||
| Unclear | 10 (12) | 5 (26) | |
| Intact | 21 (25) | 1 (5) | |
| Broken | 53 (62) | 13 (68) | |
| AJCC Stage, 8th edition | <0.001 d,* | ||
| I | 11 (14) | 0 (0) | |
| IIA | 29 (36) | 0 (0) | |
| IIB | 23 (29) | 6 (40) | |
| IIIA, IIIB, IIIC | 17 (21) | 8 (53) | |
| IV | 0 (0) | 1 (7) | |
| Monosomy 3 status (known in 103 cases) | 0.034 b,* | ||
| D3 | 37 (44) | 3 (17) | |
| M3 | 48 (57) | 15 (83) | |
| 8q status (known in 95 cases) | 0.003 b,* | ||
| No gain of 8q | 35 (45) | 1 (6) | |
| Gain of 8q | 43 (55) | 16 (94) | |
| Duplication of chromosome 6p (known in 82 cases) | 0.98 b | ||
| No gain of 6p | 31 (46) | 7 (37) | |
| Gain of 6p | 36 (54) | 8 (42) | |
| Nuclear BAP1 staining (known in 97 cases) | 0.036 b,* | ||
| Normal | 29 (37) | 2 (11) | |
| Absent | 50 (63) | 16 (89) | |
| Metastases (known in 107 cases) | 0.029 b,* | ||
| Absent | 52 (59) | 6 (32) | |
| Present | 36 (41) | 13 (68) | |
| Vital status | 0.36 d | ||
| Dead due to UM metastases | 34 (38) | 11 (58) | |
| Average follow-up time, months | 50 | 27 | |
| Dead due to other cause | 19 (21) | 0 (0) | |
| Alive at last follow-up date | 36 (40) | 8 (42) | |
* Test is significant at the 0.05 level (2-tailed). Significant p values are shown in bold. a Percentages are rounded and may not total 100; b Pearson χ2 test; c light eye colours: blue, grey, green, hazel—dark eye colour: brown; d linear-by-linear association; e Mann–Whitney U Test; f number of mitoses per mm2 with 40× magnification, in eight high power fields.